Search research articles
Contact Us
Filters
Showing results (401-410 of 564) with videos related to
Page
of 57
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
Anthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
European Urology Oncology
|
July 17, 2019
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database
Marco Moschini, Evanguelos Xylinas, Stefania Zamboni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinoma
Iman El-Hariry, Thomas Powles, Mike R Lau, et al.
Cold Spring Harbor Molecular Case Studies
|
August 31, 2023
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer
Majd Al Assaad, Gunes Gundem, Benjamin Liechty, et al.
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Page
of 57
Search research articles
Search
Showing results (401-410 of 564) with videos related to
Sort By:
Page
of 57
European Journal of Cancer (Oxford, England : 1990)
|
December 7, 2005
Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours
C N Sternberg, P de Mulder, J H Schornagel, et al.
The Journal of Urology
|
April 9, 2021
Safety and Efficacy of Atezolizumab in Understudied Populations with Pretreated Urinary Tract Carcinoma: Subgroup Analyses of the SAUL Study in Real-World Practice
Axel S Merseburger, Daniel Castellano, Thomas Powles, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 2, 2014
Randomized, controlled, double-blind, cross-over trial assessing treatment preference for pazopanib versus sunitinib in patients with metastatic renal cell carcinoma: PISCES Study
Bernard Escudier, Camillo Porta, Petri Bono, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 1, 2022
Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER
Anthony M Joshua, Andrew Armstrong, Megan Crumbaker, et al.
European Urology Oncology
|
June 16, 2019
Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials
Marco Bandini, Alberto Briganti, Elizabeth R Plimack, et al.
European Urology Oncology
|
July 17, 2019
Efficacy of Surgery in the Primary Tumor Site for Metastatic Urothelial Cancer: Analysis of an International, Multicenter, Multidisciplinary Database
Marco Moschini, Evanguelos Xylinas, Stefania Zamboni, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 20, 2010
Amplification of epidermal growth factor receptor gene in renal cell carcinoma
Iman El-Hariry, Thomas Powles, Mike R Lau, et al.
Cold Spring Harbor Molecular Case Studies
|
August 31, 2023
The importance of escalating molecular diagnostics in patients with low-grade pediatric brain cancer
Majd Al Assaad, Gunes Gundem, Benjamin Liechty, et al.
The Lancet. Oncology
|
April 19, 2015
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial
Yohann Loriot, Kurt Miller, Cora N Sternberg, et al.
Clinical Genitourinary Cancer
|
March 28, 2017
Effect of Visceral Disease Site on Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer Treated With Enzalutamide in the PREVAIL Trial
Joshi J Alumkal, Simon Chowdhury, Yohann Loriot, et al.
Page
of 57